SERUM INTERLEUKIN-6 AND C-REACTIVE PROTEIN-LEVELS CORRELATE WITH RESISTANCE TO IL-2 THERAPY AND POOR SURVIVAL IN MELANOMA PATIENTS

被引：120

作者：

TARTOUR, E

DORVAL, T

MOSSERI, V

DENEUX, L

MATHIOT, C

BRAILLY, H

MONTERO, F

JOYEUX, I

POUILLART, P

FRIDMAN, WH

机构：

[1] INST CURIE,INSERM,U255,F-75231 PARIS 05,FRANCE

[2] INST CURIE,MED ONCOL SERV,F-75231 PARIS 05,FRANCE

[3] INST CURIE,DEPT BIOSTAT,F-75231 PARIS 05,FRANCE

[4] INST CURIE,BIOCHIM LAB,F-75231 PARIS 05,FRANCE

[5] INST CURIE,HEMATOL LAB,F-75231 PARIS 05,FRANCE

[6] IMMUNOTECH SA,F-13276 MARSEILLE 9,FRANCE

来源：

BRITISH JOURNAL OF CANCER | 1994年 / 69卷 / 05期

关键词：

D O I：

10.1038/bjc.1994.175

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Interleukin 6 and C-reactive protein (CRP) were determined prior to IL-2 therapy in sera from metastatic melanoma patients. Patients with elevated serum IL-6 (> 20 pg ml(-1)) and/or CRP (> 10 mg l(-1)) levels were associated with resistance to IL-2 therapy. A correlation between high serum IL-6 levels and a shorter median survival was also observed.

引用

页码：911 / 913

页数：3

共 19 条

[1]

ADERKA D, 1989, J IMMUNOL, V143, P3517

[2] A MULTIFACTORIAL ANALYSIS OF MELANOMA .4. PROGNOSTIC FACTORS IN 200 MELANOMA PATIENTS WITH DISTANT METASTASES (STAGE III) [J].